Pluripotent human embryonic stem (hES) cells are an important experimental tool for basic and applied research, and a potential source of different tissues for transplantation. However, one important challenge for the clinical use of these cells is the issue of immunocompatibility, which may be dealt with by the establishment of hES cell banks to attend different populations. Here we describe the derivation and characterization of a line of hES cells from the Brazilian population, named BR-1, in commercial defined medium. In contrast to the other hES cell lines established in defined medium, BR-1 maintained a stable normal karyotype as determined by genomic array analysis after 6 months in continuous culture (passage 29). To our knowledge, this is the first reported line of hES cells derived in South America. We have determined its genomic ancestry and compared the HLA-profile of BR-1 and another 22 hES cell lines established elsewhere with those of the Brazilian population, finding they would match only 0.011% of those individuals. Our results highlight the challenges involved in hES cell banking for populations with a high degree of ethnic admixture.
INTRODUCTION
As for other sources of tissues and cells for transplantation, the risk of immune rejection of hES-derived cells is correlated with the presence of cell surface antigens The pluripotency of embryonic stem (ES) cells has rendered them a potential source of tissues for transplan-at the major histocompatibility complex (MHC), in humans represented by the HLA (human leukocyte anti-tation. For the last two decades, this property has been demonstrated in animal models of several conditions, in-gen) proteins. Thus, the higher the similarity among HLA types, the lesser the chance of rejection, increasing cluding diabetes [reviewed in (19) ], spinal cord injury, and Parkinson's disease [reviewed in (14) ]. The estab-the likelihood of transplant survival (31) . However, the genes encoding for HLA are very polymorphic in our lishment of hES cells in 1998 (35) has increased the expectations regarding the therapeutic use of these cells species (34) , making it extremely difficult to obtain a perfect match between donor and recipient. in patients. However, in addition to the concerns about the tumorigenic potential of hES cells, issues regarding
A review of the literature shows that the issue of the immunogenicity of hES cell-derived tissues is still not the immunogeneicity of tissues derived from these cells, and the standardization of production of cells as pharma-clear. These cells express HLA-I genes, albeit in lower levels than somatic cells do (9). On the other hand, these cological agents may hinder their use in humans. pluripotent cells show imunogeneicity in mice, where MATERIALS AND METHODS immunosuppressive therapy must be employed in order Establishment of hES Cell Lines to avoid rejection of hES cells by the host immune sys-Couples donated surplus embryos from in vitro fertiltem (32) . ization (IVF) cycles according to the Brazilian legisla-Strategies to reduce immunogenicity of allogenic tion (Bio-safety Law 11.105, March 25, 2005) , signing hES cell-derived grafts include the generation of patientthe informed consent, and with the approval of the Ethspecific cell lines by somatic cell nuclear transfer [re- ics Committee of the Instituto de Biociências of the Univiewed in (39) ] or by reprogramming adult cells into a versidade de São Paulo. Whole embryos at blastocyst pluripotent state [induced pluripotent stem (iPS) cells] stage or mechanically dissected inner cell masses were with different transcription factors [reviewed in (38) ].
plated on four-well plates coated with hES-certified Ma-Although in theory these methods would circumvent the trigel (BD Biosciences) and cultured with mTeSR1 deissue of immunocompatibility, the generation of autolofined medium (StemCell Technologies), a serum-free gous tissues for transplantation is in practice extremely medium that includes high levels of growth factors like demanding and expensive. Furthermore, current meth-bFGF and TGF-β. No additional component was added ods for generating iPS cells involve genetic modificato the medium. After 48 h, half of the medium was tions, which increase the risk of their therapeutic use.
changed every other day for 7-12 days. Outgrowths Finally, because patient-specific pluripotent cell lines were mechanically passaged into new wells coated with would not be universal therapeutic agents, each cell line Matrigel or mouse irradiated feeder cells (MEFs; Chemgenerated will probably be treated as a separate product, icon Millipore). After the first passage (p1), half-medium and in that case will have to go through extensive prechange was performed every day with mTeSR1. Coloclinical and clinical testing before being approved by the nies were mechanically passaged every 5-7 days, and regulatory bodies for therapeutic use (7).
after the third passage half of the cell clumps obtained An alternative to reduce immunogenicity of allogenic from mechanical dissociation of the colonies was frozen hES cell-derived grafts is banking of MHC-compatible in 90% fetal bovine serum (FBS, Hyclone) and 10% hES cell lines (33) . It is still debatable how many geneti-DMSO (Sigma). cally diverse cell lines such a bank would need in order to attend different populations. The numbers vary from Immunocytochemistry hundreds (28, 33) to millions (5, 8) 
of lines, depending
Cells from passages 6 and 29 were fixed and immuon the acceptable degree of immune mismatch, and on nostained following standard protocols. Briefly, cells the genetic diversity of the population under considerwere fixed with 4% paraformaldehyde for 10 min, permeation. abilized in 0.1% Triton X-100 solution (Sigma), and Equally important for regenerative therapies is the blocked in 1% fetal bovine serum (FBS; Hyclone) for standardization of defined conditions and processes to 1 h. Cells were then incubated with primary antibodies be used in manufacturing hES cell-based therapeutic overnight at 4°C, washed in PBS, and incubated with cells (i.e., culture and differentiation of the cells) (11).
Cy3-conjugated mouse IgG antibodies (1:200; GE Although the culture of hES cells in defined medium Healthcare) for 60 min at room temperature. Slides were has been reported by different groups (24, 40) , there is prepared using Vectashield with DAPI (Vector Laboraonly one report of the establishment of new lines of hES tories, Inc) for nuclei counterstaining. Primary antibodcells in defined medium (25) . However, one of the lines ies used were: monoclonal anti-mouse stage-specific was aneuploid already in early passages, while the other embryonic antigen-1 (SSEA-1) and -4 (SSEA-4), TRAbecame aneuploid after 4-7 months in culture.
1-60, TRA-1-81 (dilution 1:50; Chemicon), and anti-Here we describe the derivation of a new hES cell mouse OCT-4 (dilution 1:100; Santa Cruz Biotechnolline, called BR-1, using a defined commercial medium. ogy, Inc.) Human foreskin fibroblasts (HS27 cell line, This hES cell line expresses markers of pluripotency, ATCC) were used as negative controls. can be differentiated into tissues of the three germ layers, and presents a stable normal karyotype after 6
In Vitro Differentiation months of continuous culture in defined medium. We compare its HLA profile to those of a subset of the Bra-For embryoid body (EBs) formation, cell aggregates were grown in suspension in nonadherent plates as de-zilian population, and discuss the implications for hES cell-based therapy in ethnically diverse populations. To scribed by Itskovitz-Eldor et al. (16) . The differentiation medium consisted of 80% DMEM, 20% FBS (Hyclone), our knowledge, BR-1 is the first hES cell line derived in South America, and the characterization of its genomic 1% Glutamax (Invitrogen), and 1% penicillin-streptomicin (Invitrogen). After 1 week, EBs were collected and ancestry raises important issues regarding hES cell banking to attend genetically admixed populations. transferred to 0.1% gelatin-coated dishes for one more
week, and then fixed in 4% PFA and subjected to immu-ing CGH Analytics software 3.4.40 (both from Agilent Technologies) with the statistical algorithm ADM-2, and nocytochemistry assay as described above. The primary antibodies used were: endoderm: anti-goat SOX-17 and sensitivity threshold 6.0. At least three consecutive oligonucleotides had to have aberrant log 2 ratios to be anti-goat HNF-3β (Santa Cruz Biotechnology, Inc.); mesoderm: α-actinin (Sigma), and mouse anti-MYOD called by the software. The average resolution was approximately 70 kb. (BD Pharmingen); ectoderm: MAP2 (Sigma) and NF200 (Sigma). For secondary antibodies anti-goat IgG-FITC HLA Typing and Analysis of Genomic Ancestry (Santa Cruz Biotechnology, Inc.) or anti-mouse IgG-Cy3 (GE Healthcare) were used.
Genomic DNA from BR-1 was used for HLA-typing of loci A, B, Cw, DRB1, and DQB1 at medium resolu-Teratoma Assays tion, and was performed by the Laboratório de Histocompatibilidade (UNIFESP, Brazil) using the LABType Cells from passage 12 were cultured both on Matrigel and on feeder cells. Undifferentiated colonies were dis-SSO typing system according to the manufacturer's instructions (OneLambda, Inc). HLA profile of different sected mechanically, and approximately 100 cell aggregates (approximately 1 × 10 5 cells) were injected subcu-hES cell lines was obtained from the literature (17, 21) or from the International Stem Cell Registry (15) and taneously in C57/Bl6 nude mice. Teratoma formation was followed for 10-12 weeks after injection. Tumors the European Human Embryonic Stem Cell Registry (10). HLA matching at low resolution for loci A, B, and were dissected, fixed in 4% PFA, embedded in paraffin, and submitted to histological analysis as described (35) .
DRB1 was performed against 1,312,334 individuals from the Brazilian National Registry of Bone Marrow Karyotype and Microarray Comparative Genomic Donors (REDOME) using the Sismatch software (4).
Hybridization (CGH) Analysis
Genomic ancestry was determined by analysis of 40 insertion/deletion (indel) polymorphisms along the au-Standard G-banding karyotype analysis was pertosomes as described by Bastos-Rodrigues et al. (3) . formed in BR-1 cells from passage 6 and passage 29 as These experiments were performed by Laboratório Gene described elsewhere (13). At least 20 metaphases were (Belo Horizonte, MG, Brazil). analyzed in each group. CGH-array was performed using an array containing 44,000 oligonucleotides (Human RESULTS Genome Microarray CGH 44A, Agilent Technologies), as described elsewhere (20) . Briefly, genomic DNAs Seventy-nine surplus embryos produced for reproductive purposes were thawed and allowed to develop from passages 4 and 29 of BR-1, and a normal female were labeled by random priming with Cy3-and Cy5-until the blastocyst stage, on day 5. Inner cell masses (ICM) were mechanically isolated from 5 of a total of dCTPs, respectively. Purification, hybridization, and washing were carried out as recommended by the manu-45 blastocysts obtained, and the other 40 poor quality blastocysts had only the zona pellucida (ZP) mechani-facturer. Scanned images of the arrays were processed with Agilent Feature Extraction v9.5.1 and analyzed us-cally removed. Both isolated ICMs and whole blasto- cysts were plated on Matrigel-coated plates and cultured ing tightly, compact colonies that were mechanically dissociated every 6-8 days and cultured in feeder-free in mTeSR1 medium (StemCell Technologies). From this day on, outgrowths were observed and had half of the conditions (Fig. 1 ). This line, named BR-1, was successfully propagated and characterized. medium changed every other day until the first passage (p1), after which complete medium change was per-Cells were assayed for antigens correlated with pluripotency by immunofluorescence ( Fig. 2 ). Colonies show formed every day.
Twenty one plated blastocysts (3 isolated ICMs and a clear nuclear staining pattern for OCT4, and cell surface staining for TRA-1-60, TRA-1-81, and SSEA-4. 18 whole blastocysts) attached and grew in culture with mTeSR1 and Matrigel for 7-10 days. We then added
We verified the potential of BR-1 cells to differentiate into the three germ lineages in vitro. Cells were cul-mouse irradiated feeder cells (MEFs) to 7 surviving outgrows, and 13 days later, cell clumps from one outgrow tured in basic medium without FGF in nonadherent culture plates, allowing the formation of embyoid bodies (from a whole blastocyst) were mechanically passaged to Matrigel-coated dishes with mTeSR1. Colonies ex-(EBs). After 1 week in suspension, EBs were transferred and cultured 1 more week in gelatin-coated wells. Im-hibited the characteristic morphology of hES cells, with each cell showing a high nucleus/cytoplasm ratio, form-munostaining of differentiated cell confirmed differenti-ation in endoderm [SOX17 and HNF3β (FOXA)], meso-male reference sample were detected. These data indicate that the culture conditions were adequate for deriva-derm (α-actinin and MYOD), and ectoderm [NF200 (NEFH) and MAP2] (Fig. 3) .
tion and propagation of a karyotypically normal and stable hES cell line. BR-1 has also been successfully Pluripotency of BR-1 cells was also tested by teratoma formation assays. Ten to 12 weeks after subcutane-propagated on MEFs from passage 2 on, and will be characterized at a later date. ous injection of undifferentiated cell clumps into nude mice, tumors with both cystic and solid areas were visu-
The HLA profile at low resolution of BR-1 and those of 22 other hES cell lines was compared with the Brazil-alized. Histological analysis of the teratomas revealed the presence of tissues derived from mesoderm, endo-ian Bone Marrow Donor Registry (REDOME), consisting of HLA typing of 1,312,334 Brazilians ( Table 1 ). In that derm, and ectoderm, demonstrating the pluripotency of BR-1 ( Fig. 4) .
subset of the Brazilian population we found no full match for BR-1, nor for cell lines derived in Israel, In-Chromosomal stability of BR-1 was assayed by both conventional karyotyping and by CGH-array ( Fig. 5) .
dia, or Spain. In contrast, at least one full match was found to lines established in the US, Singapore, and Cells at passage 6 and 29 were karyotyped by standard G-banding. At least 20 metaphases were counted, all Sweden. Taken together, the 23 lines analyzed were a match for 0.011% (150/1,300,000) of the Brazilian pop-showing a normal 46,XY chromosome constitution (Fig.  5A ). For analysis at higher resolution, CGH-array was ulation represented in REDOME's database.
Genotyping of 40 indel polymorphisms on autosomes performed, detecting no chromosomal loss or gain at the 70-kb resolution in cells cultured continuously for 6 (genotypes available upon request, or at www.ib.usp.br/ lance_usp) revealed that the genomic ancestry of BR-1 months, at passage 29 (Fig. 5B ). As a positive control, sex chromosome imbalances between BR-1 and the fe-is 98.4% European, 0.8% Amerindian, and 0.8% African ( Table 2 ). The same analysis showed that the genomic medium, TeSR, which differs from mTeSR1 used in this study only by the replacement of bovine by human albu-ancestry of H1 is also predominantly European (96.0%).
min (25, 26) . However, while one cell line was aneuploid in early passages, perhaps due to an alteration already DISCUSSION present in the original embryo, the second line became trisomic for chromosome 12 after 7 months in culture. As of August 2009 there were more than 300 different lines of hES cells deposited in the International Stem
In contrast, BR-1 remained karyotypically stable at passage 29 even at the 70-kb resolution. Therefore, our re-Cell Registry (15). Therefore, what are the motivations to establish new lines? One important reason is the stan-sults show that a defined medium can support the establishment of a karyotipically normal hES cell line. We dardization of protocols for derivation and in vitro maintenance of hES cells. In particular, defined conditions are currently working on the establishment of new hES cell lines in defined xeno-free medium, which will fur-for establishing and culturing hES cell should facilitate replication of experiments with those cells in both the ther facilitate the clinical use of tissues derived from those cells. basic research and clinical settings. Although defined conditions for culturing hES cells have been described
The second issue relates to the need to increase the diversity of HLA types in stem cell banks, which in turn by several groups [reviewed in (37)], to date there is only one report of derivation of hES cell lines in defined will be important to cater to ethnically heterogeneous populations in the clinical setting. HLA genes are among lines were full matches at low resolution to only 0.011% of the Brazilian population. This is in strong contrast the most polymorphic in the entire genome (18, 34) . There are hundreds of reported alleles for each locus, with results obtained by a similar analysis performed in the Chinese population (23), where it was found that a and the number is still rising as new ones are described. Currently, there is little information about HLA allele local hES cell bank with 188 lines provides a full match to 24.9% of that population. It will be important to have frequencies in admixtured populations (1). In particular, Brazil has a population of approximately 190 million a greater number of hES cell lines derived from the Brazilian population in order to evaluate whether interna-individuals with a uniquely high degree of admixture, having different degrees of African, European, and Am-tional or national hES cell banks may better cater to this population. erindian ancestry (30) . For Brazilian patients subjected to bone marrow transplants, most nonconsanguineous do-Finally, another motivation for the derivation of new hES cell lines is to increase the number of genetically nors are found within the Brazilian population. Therefore, we hypothesized that BR-1 would be a better match for variant cell lines available for research and therapy. Indeed, two recent studies of the genetic background of 86 the Brazilian population than hES cells derived elsewhere. However, BR-1 was a worse match to the Brazilian sub-hES cell lines concluded that, despite being from different geographical areas, they were from very restricted population represented by approximately 1.3 million individuals registered at the REDOME than seven lines de-ethnic origins, basically European and Middle Eastern/ East Asian (22, 27) . Both studies concluded that there is rived elsewhere (Table 1) . Interestingly, the hES cell lines with most matches to individuals in that register currently a lack of representative lines from populations worldwide, and reinforced the need for derivation of were derived in the USA (H1; 51 matches) and Singapore (HES4; 58 matches). Nevertheless, those 23 cell hES cells from underrepresented groups. The Brazilian population is one of the most heteroge-in general does not include cryopreservation of surplus embryos, and therefore the only material available for neous worldwide, a result of its history of colonization and five centuries of interethnic crosses among Europe-research comes from private clinics. Assuming that only those couples with a monthly income above 10 mini-ans (mostly Portuguese), Africans, and Amerindians (29) . Therefore, the genomes of most Brazilians are mosaics, mum wages (approximately US$2,500) are able to afford the high cost of private assisted reproduction, that having alleles from different phylogeographical origins (29) . The high degree of admixture of the Brazilian pop-Brazilian subpopulation would be mostly composed of people self-identified as caucasian (81% according to ulation can thus be explored for the derivation of hES cell lines with novel genetic backgrounds. However, the the demographic census of year 2000 from the Brazilian Institute of Geography and Statistics) (6). Despite the analysis of the genomic ancestry of BR-1 showed that it is mostly of European origin (98.4%), similar to the H1 limitations of this classification (30) , that group is likely not representative of the Brazilian ethnic admixture. line derived in the US, and not representative of the mosaic genome characteristic of the Brazilian population, Therefore, in order to explore the full genetic diversity where the European contribution ranges from 37% to 82% (30). 
